Literature DB >> 23901950

The roles of canonical and non-canonical Wnt signaling in human de-differentiated articular chondrocytes.

N Sassi1, L Laadhar, M Allouche, B Zandieh-Doulabi, M Hamdoun, J Klein-Nulend, S Makni, S Sellami.   

Abstract

Osteoarthritis is the most prevalent form of arthritis in the world and it is becoming a major public health problem. Osteoarthritic chondrocytes undergo morphological and biochemical changes that lead to de-differentiation. The involvement of signaling pathways, such as the Wnt pathway, during cartilage pathology has been reported. Wnt signaling regulates critical biological processes. Wnt signals are transduced through at least three intracellular signaling pathways including the canonical Wnt/β-catenin pathway, the Wnt/Ca2 + pathway and the Wnt/planar cell polarity pathway. We investigated the involvement of the Wnt canonical and non-canonical pathways in human articular chondrocyte de-differentiation in vitro. Human articular chondrocytes were cultured through four passages with no treatment, or with sFRP3 treatment, an inhibitor of Wnt pathways, or with DKK1 treatment, an inhibitor of the canonical pathway. Chondrocyte-secreted markers and Wnt pathway components were analyzed using western blotting and qPCR. Inhibition of the Wnt pathway showed that the canonical Wnt signaling probably is responsible for inhibition of collagen II expression, activation of metalloproteinase 13 expression and regulation of Wnt7a and c-jun expression during chondrocyte de-differentiation in vitro. Our results also suggest that expressions of eNOS, Wnt5a and cyclinE1 are regulated by non-canonical Wnt signaling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23901950     DOI: 10.3109/10520295.2013.819123

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  7 in total

1.  Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/β-catenin signaling pathways.

Authors:  Shuan Liu; Hongping Yang; Bing Hu; Mingyong Zhang
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

Review 2.  The osteocyte as a therapeutic target in the treatment of osteoporosis.

Authors:  Gaël Y Rochefort
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

3.  Comparative proteomic analysis of hypertrophic chondrocytes in osteoarthritis.

Authors:  Konstantinos C Tsolis; Ekaterini S Bei; Ioanna Papathanasiou; Fotini Kostopoulou; Vassiliki Gkretsi; Kalliopi Kalantzaki; Konstantinos Malizos; Michalis Zervakis; Aspasia Tsezou; Anastassios Economou
Journal:  Clin Proteomics       Date:  2015-04-25       Impact factor: 3.988

4.  Inactivation of Fam20B in Joint Cartilage Leads to Chondrosarcoma and Postnatal Ossification Defects.

Authors:  Pan Ma; Wenjuan Yan; Ye Tian; Jingya Wang; Jian Q Feng; Chunlin Qin; Yi-Shing Lisa Cheng; Xiaofang Wang
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

5.  The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway.

Authors:  Linwei Chen; Yaosen Wu; Yan Wu; Ye Wang; Liaojun Sun; Fangcai Li
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

6.  Psoralen promotes the expression of cyclin D1 in chondrocytes via the Wnt/β-catenin signaling pathway.

Authors:  Wenwei Zheng; Pingdong Lin; Yuhuan Ma; Xiang Shao; Houhuang Chen; Da Chen; Xianxiang Liu; Xihai Li; Hongzhi Ye
Journal:  Int J Mol Med       Date:  2017-09-21       Impact factor: 4.101

7.  Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.

Authors:  Ekaterina Balaian; Manja Wobus; Heike Weidner; Ulrike Baschant; Maik Stiehler; Gerhard Ehninger; Martin Bornhäuser; Lorenz C Hofbauer; Martina Rauner; Uwe Platzbecker
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.